1. Home
  2. TGTX vs QLYS Comparison

TGTX vs QLYS Comparison

Compare TGTX & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.73

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$170.72

Market Cap

6.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
QLYS
Founded
1993
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
6.3B
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
TGTX
QLYS
Price
$54.73
$170.72
Analyst Decision
Strong Buy
Hold
Analyst Count
5
13
Target Price
$49.80
$133.08
AVG Volume (30 Days)
1.8M
540.8K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
1746.67
16.99
EPS
0.17
2.91
Revenue
$2,785,000.00
$321,607,000.00
Revenue This Year
$49.08
$9.97
Revenue Next Year
$26.69
$7.15
P/E Ratio
$326.94
$58.53
Revenue Growth
N/A
15.32
52 Week Low
$26.76
$74.51
52 Week High
$59.30
$201.54

Technical Indicators

Market Signals
Indicator
TGTX
QLYS
Relative Strength Index (RSI) 59.68 46.00
Support Level $51.51 $128.98
Resistance Level $58.04 $193.85
Average True Range (ATR) 2.70 7.06
MACD 0.29 -3.15
Stochastic Oscillator 78.59 13.87

Price Performance

Historical Comparison
TGTX
QLYS

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

Share on Social Networks: